Transforming Oncology

Advancing GBM treatment through pioneering research and transformative therapies for improved patient outcomes.

Publications & Presentations

CNS Pharmaceuticals Recently Announced it has Expanded its Pipeline with In-License of Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Company Hosted Webcast July 30th

View Press Release

Access Webcast Replay

Our Focus

Our primary focus is on glioma, specifically glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.

Learn More about Our Focus

For Patients

CNS Pharmaceuticals is dedicated to supporting patients and their families throughout their cancer journey. Our 'For Patients' page offers valuable resources, including information about our clinical trials, treatment options, and support networks. Visit our 'For Patients' page to learn more and find the help you need.

Learn More about For Patients

Our Pipeline

Our primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.

Learn More about Our Pipeline

Latest News

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Read More of CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Read More of CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules

Read More of CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules
See All News Releases

Investor Relations

Explore our financial data and market performance. Get a clear picture of our strategic outlook.

Learn More about Investor Relations

Presentations

Access our comprehensive publications and presentations page for information on our research programs.

Learn More about Publications & Presentations

Email Alerts

Get timely updates on our latest developments. Subscribe to email alerts for new press releases, events, and filings.

Learn More about Investor Relations

Pipeline

Track our ongoing research and development projects. Monitor the progress and future of our drug programs.

Learn More about Pipeline